Patents Assigned to Ipsen Pharma S.A.S.
  • Use of botulinum toxin for the preparation of a medicament for the treatment of lithiasis of salivary gland, gall bladder, kidney, or pancreas
    Patent number: 7838009
    Abstract: The invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat a gland, organ or duct obstructed by a naturally formed stone. This method can be applied notably for salivary gland, gall bladder, kidney or pancreas stones.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: November 23, 2010
    Assignees: Ipsen Pharma S.A.S., Ipsen Biopharm Limited
    Inventors: Pierre Bernard D'Arbigny, Piere-Etienne Chabrier De Lassauniere, Alan Barcock
  • Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments
    Patent number: 7816539
    Abstract: A subject of the present Application is novel derivatives of benzimidazole and imidazopyridine which have a good affinity for certain sub-types of melanocortin receptors, in particular the MC4 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more melanocortin receptors are involved. The invention also relates to pharmaceutical compositions containing said products.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: October 19, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Lydie Poitout, Valerie Brault, Carole Sackur, Pierre Roubert, Pascale Plas
  • Peptide YY analogs
    Patent number: 7811989
    Abstract: The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: October 12, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • PYRIMIDO-BENZIMIDZOLE DERIVATIVES AND THE USE THEREOF IN THE FORM OF AGONISTS OR ANTAGONISTS OF MELANOCORTIN RECEPTORS
    Publication number: 20100256135
    Abstract: The invention relates to novel pyrimido-benzimidazole derivatives. Said products exhibit a good affinity for certain melanocortin receptor sub-types, in particular MC4 receptors. Said products represent a particular interest for treating pathological disorders and diseases associated with one or several melanocortin receptors. Pharmaceutical compositions containing said products and the use thereof for a drug preparation are also disclosed.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 7, 2010
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Lydie POITOUT, Carole Sackur, Valérie Brault, Pierre Roubert, Pascale Plas
  • Method of treating osteoporosis comprising administration of PTHrP analog
    Patent number: 7803770
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: September 28, 2010
    Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses
    Patent number: 7795284
    Abstract: A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: September 14, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Marie-Odile Galcera-Contour, Grégoire Prevost, Alban Sidhu
  • Stable pharmaceutical composition containing factor VIII
    Patent number: 7790680
    Abstract: The invention relates to a stable solid pharmaceutical composition comprising factor VIII. Such a composition is devoid of amino acids and comprises: (a) factor VIII; (b) a surfactant; (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate; and (g) a buffer devoid of amino acids; and has a pH from 6 to 8 prior to lyophilization and after reconstitution in water for injection. The invention also relates to the liquid pharmaceutical composition obtainable after dilution of said stable solid pharmaceutical composition with sterile water optionally containing sodium chloride.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: September 7, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Mary White, Paul Webb
  • PYRAZOLO-PYRAZINES DERIVATIVES USED AS G PROTEIN INHIBITORS
    Publication number: 20100222332
    Abstract: The invention relates to pyrazolo-pyrazines derivatives of the general formula (I) in which the radicals Z, R1, R2, R3 and R4 represent various variable groups, X is a sulphur atom or a selenium atom, and n is an integer equal to 1 or 2. These compounds are inhibitors of G proteins. They are of particular interest for treating diseases in which the heterotrimeric G protein is involved. The invention also relates to pharmaceutical compositions containing said products, and to the use thereof for preparing a drug.
    Type: Application
    Filed: September 25, 2008
    Publication date: September 2, 2010
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Olivier Lavergne, Laetitia Brehu, Gregoire Prevost
  • Sustained release formulations comprising very low molecular weight polymers
    Publication number: 20100209384
    Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.
    Type: Application
    Filed: October 26, 2007
    Publication date: August 19, 2010
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado, Frédéric Lacombe, Laurence Lachamp, Didier Bourissou
  • Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists and antagonists of melanocortin receptors
    Patent number: 7763725
    Abstract: The invention relates to novel pyrimido-benzimidazole derivatives. Said products exhibit a good affinity for certain melanocortin receptor sub-types, in particular MC4 receptors. Said products represent a particular interest for treating pathological disorders and diseases associated with one or several melanocortin receptors. Pharmaceutical compositions containing said products and the use thereof for a drug preparation are also disclosed.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: July 27, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Lydie Poitout, Carole Sackur, Valerie Brault, Pierre Roubert, Pascale Plas
  • Botulinum toxin for the treatment of reduction of hair growth
    Patent number: 7754253
    Abstract: The use of botulinum toxin for preparing a drug for preventing hair growth is disclosed. A cosmetic method for preventing hair growth is also disclosed.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: July 13, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Claude LeLouarn
  • TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE
    Publication number: 20100137275
    Abstract: The present invention relates to the novel triaminopyrimidine derivatives of formula (I) in which R1, R2, W, R3, R4, and R5 are variable groups. These products have a Cdc25-phosphatase-inhibiting activity. The invention also relates to a process for synthesizing these compounds and also to therapeutic compositions containing these products and to the use thereof as medicaments.
    Type: Application
    Filed: April 30, 2008
    Publication date: June 3, 2010
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Grégorie Prevost, Anne-Marie Liberatore, Dennis Bigg, Dominique Pons
  • Prenyl transferase inhibitors
    Patent number: 7691859
    Abstract: A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R25); and the remaining substituents are as defined in the disclosure.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: April 6, 2010
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Thomas D. Gordon, Barry A. Morgan
  • PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT
    Publication number: 20100056507
    Abstract: The present invention relates to new phenylic derivatives exhibiting a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. These derivatives are of particular interest in a method for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said new phenylic derivatives and to methods for the preparation and use thereof.
    Type: Application
    Filed: October 26, 2007
    Publication date: March 4, 2010
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Lydie Poitout, Jeremiah Harnett, Dennis Bigg, Carole Sackur, Eric Ferrandis
  • Method for decreasing body weight using a somatostatin receptor agonist
    Patent number: 7662784
    Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: February 16, 2010
    Assignee: Ipsen Pharma, S.A.S.
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING THE PAIN INDUCED BY THERAPEUTIC TREATMENTS FOR THE AIDS VIRUS
    Publication number: 20100029566
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Application
    Filed: December 17, 2007
    Publication date: February 4, 2010
    Applicant: IPSEN PHARMA S.A.S
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • USE OF CLAYS FOR TREATING COELIAC DISEASE
    Publication number: 20100003348
    Abstract: The invention relates to the use of a clay for the preparation of a medicament for treating coeliac disease. Preferably, the clay used is of smectite type.
    Type: Application
    Filed: February 6, 2008
    Publication date: January 7, 2010
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Héléne Mathiex-Fortunet
  • Pyrimidinone Derivatives and Their Use as a Drug
    Publication number: 20090325933
    Abstract: The present application relates to new pyrimidinone derivatives. These products have a good affinity for certain sub-types of cannabinoid receptors, especially the CB2 receptors. They are particularly attractive for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a drug.
    Type: Application
    Filed: July 13, 2007
    Publication date: December 31, 2009
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Lydie Poitout, Carole Sackur, Eric Ferrandis
  • Imidazolyl derivatives
    Patent number: 7638546
    Abstract: The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 29, 2009
    Assignee: IPSEN Pharma S.A.S.
    Inventors: Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Thomas D. Gordon, Barry A. Morgan, Christophe Philippe Moinet, Dennis C. H. Bigg
  • PRODUCT COMPRISING A TRANSDUCTION INHIBITOR OF HETEROTRIMERIC G PROTEIN SIGNALS COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN THE TREATMENT OF CANCER
    Publication number: 20090270341
    Abstract: A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered simultaneously, separately or spread over a period of time and a pharmaceutical carrier.
    Type: Application
    Filed: July 2, 2009
    Publication date: October 29, 2009
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Gregoire PREVOST, Marie-Odile Lonchampt, Thomas Gordon, Barry Morgan